(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of 124.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Abivax Sa's revenue in 2025 is $8,977,906.On average, 3 Wall Street analysts forecast ABVX's revenue for 2025 to be $553,201,748, with the lowest ABVX revenue forecast at $372,902,244, and the highest ABVX revenue forecast at $901,814,611. On average, 2 Wall Street analysts forecast ABVX's revenue for 2026 to be $535,888,429, with the lowest ABVX revenue forecast at $372,902,244, and the highest ABVX revenue forecast at $698,874,614.
In 2027, ABVX is forecast to generate $7,267,725,217 in revenue, with the lowest revenue forecast at $5,715,931,847 and the highest revenue forecast at $9,673,895,972.